Announcements Trials
Browse Landscape

Phase

Phase 1 55Phase 2 50Phase 1/2 25Phase NA 15Phase 3 4Phase EARLY_PHASE1 3Phase 2/3 2

Status

Terminated 2Completed 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Breast Neoplasms 13Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 9Recurrence 6Prostatic Neoplasms 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Squamous Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Melanoma 4Liver Neoplasms 4Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Hematologic Neoplasms 3Fatigue 3Esophageal Neoplasms 3Endometrial Neoplasms 3Depression 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2

Interventions

umbralisib 1ublituximab 1fludarabine 1Whole-Body Irradiation 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Lymphoma, Mantle-Cell × Clear all
NCT02793583 2022-07-21

UNITY-NHL

TG Therapeutics, Inc.

Phase 2/3 Terminated
710 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00714259 2017-07-24

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

University of Alabama at Birmingham

Phase 2/3 Terminated
5 enrolled 11 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡